Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Bionik Laboratories Corp. (the "Company") on Form 10-K for the annual period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Rich Russo Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
Date: June 21, 2023
|
| /s/ Rich Russo Jr. |
| | Rich Russo Jr. |
| | Chief Executive Officer |
| | (Principal Executive Officer) |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Bionik Laboratories Corp. (the "Company") on Form 10-K for the annual period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dan Gonsalves, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
Date: June 21, 2023
|
| /s/ Dan Gonsalves |
| | Dan Gonsalves |
| | Chief Financial Officer |
| | (Principal Financial and Accounting Officer) |